James F. Cummings - 28 Mar 2026 Form 4 Insider Report for Vaxart, Inc. (VXRT)

Reporting relationship: Chief Medical Officer
Issuer ticker: VXRT
Reported as of: 28 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2026, 16:44:09 UTC
Prior SEC filing: 26 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Edward Berg, Attorney-in-Fact

Key filing fact

James F. Cummings filed Form 4 for Vaxart, Inc. (VXRT) on 31 Mar 2026.

Key facts

This page summarizes James F. Cummings's Form 4 filing for Vaxart, Inc. (VXRT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Mar 2026, 16:44.

Change

Previous filing in this sequence was filed on 26 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001886760 Primary reporting owner

Cummings James F.

Relationship: Chief Medical Officer
Address: C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Edward Berg, Attorney-in-Fact
Signature date: 31 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VXRT transaction

Common Stock

Tax liability

Transaction value
Shares: -3,292
Change %: -0.35%
Price: $0.6500^*
Shares after: 924,177
Date: 28 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026.

Footnote F2

This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.